英夫利昔单抗-类克在激素抵抗及激素依赖溃疡性结肠炎治疗中的应用  

Efficacy of infliximab in the management of steroidrefractory or steroid-dependent ulcerative colitis

作　　者：李懿璇[1] 李世荣[2] 李俊霞[1] 杨欣艳[2] 王化虹[1] 

机构地区：[1]北京大学第一医院消化内科,北京市100034 [2]中国人民解放军北京军区总医院消化内科,北京市100700

出　　处：《世界华人消化杂志》2012年第21期1987-1992,共6页World Chinese Journal of Digestology

摘　　要：目的:评价英夫利昔单抗(类克)对于激素抵抗及激素依赖的中重度溃疡性结肠炎(ulcerativecolitis,UC)的治疗效果.方法:回顾性分析2009-04/2011-11在北京大学第一医院及中国人民解放军北京军区总医院消化内科住院治疗的,因激素抵抗或激素依赖而接受类克治疗的中重度UC患者共19例的临床资料.结果:19例患者中10例达到临床缓解,其中2例达到黏膜愈合,7例治疗有效,治疗总有效率是89.47%,缓解率是52.63%;治疗有效者,血红蛋白(hemoglobin,Hb)及白蛋白(albumin,ALB)均明显上升,血沉(erythrocyte sedimentation rate,ESR)及C反应蛋白(Creaction protein,CRP)明显下降.5例具有肠外表现者的肠外症状都得到改善.观察期间未发生严重不良反应.结论:类克对于激素抵抗及激素依赖的中重度UC国人具有良好的治疗效果,同时安全性较好,为难治性UC患者的治疗开拓了新途径.AIM：To evaluate the efficacy of infliximab（Remicade） in the management of steroid-refractory and steroid-dependent moderate to severe ulcerative colitis（UC）.METHODS：The clinical data for 19 steroidrefractory or steroid-dependent moderate to severe UC patients who accepted treatment with infliximab in the Peking University First Hospital and the General Hospital of Beijing Military Command of Chinese PLA from April 2009 to November 2011 were analyzed retrospectively.RESULTS：Ten patients achieved clinical remis-sion,of whom 2 achieved mucosal healing,and 7 achieved clinical response.The total response rate was 89.47%,and remission rate was 52.63%.In all the patients responding to the treatment,Hb and ALB rose apparently,and ESR and CRP decreased obviously.The extraintestinal symptoms in 5 patients with extraintestinal manifestations were improved.No serious adverse events occurred.CONCLUSION：Infliximab is effective and safe in the management of steroid-refractory or steroid-dependent moderate to severe UC patients.

关 键 词：溃疡性结肠炎 激素抵抗 激素依赖 英夫利昔单抗(类克) 

分 类 号：R574.62[医药卫生—消化系统]